Wyeth Receives First Approval For Prevenar 13

The Chilean Ministry of Health has approved Wyeth’ Prevenar 13 Valent, (Diphtheria CRM197 Protein) for infants and young children.

Prevenar 13 Valent is approved for immunization of children aged 6 weeks through 5 years, for the prevention of invasive pneumococcal disease, as well as pneumonia and otitis media caused by 13 pneumococcal serotypes.

Emilio Emini, executive vice president of Vaccines Research and Development at Wyeth, said: The approval of Prevenar 13 in Chile is the first of many regulatory decisions we anticipate receiving around the world this year. We believe that Prevenar 13 is an important milestone in Wyeth’s ongoing commitment to public health in the fight against serious pneumococcal disease worldwide.”